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Background: Cardiovascular disease in the context of human immunodeﬁciency virus infec-
tion  has become a major clinical concern in recent years. In the current report we assess
hospitalizations due to cardiovascular disease in human immunodeﬁciency virus patients
in  a Social Security reference hospital in Peru.
Methods: A retrospective study was carried out between January 1996 and December 2012 in
a  General Hospital in Lima, Peru.
Results: We  included 26 patients hospitalized due to cardiovascular disease. Mean age was
46.3  years (SD 12.5), predominantly male (57.7%). Ten patients (38.4%) were in Acquired
Immunodeﬁciency Syndrome stages. Seventeen (65.4%) received high-active-antiretroviral
therapy. Eleven (42.3%) had cardiac involvement and 15 (57.7%) had non-cardiac vascular
involvement. The most frequent causes of cardiac involvement were pericardial effusion
and  myocardial infarction. On the other hand, deep vein thrombosis and stroke were the
most frequent for non-cardiac vascular involvement.
Conclusions: Cardiovascular disease is an important cause of hospitalization in Peruvianhuman immunodeﬁciency virus patients, with differences between immunosuppression
stages. Further studies analyzing associated factors are warranted.
© 2015 Elsevier Editora Ltda. All rights reserved.∗ Corresponding authors.
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Human immunodeﬁciency virus (HIV) infection has been
characterized by signiﬁcant immunosuppression states that
predispose patients to opportunistic infectious and neo-
plasias, as well as progressive dysfunction of organs and
systems.1 Since 1981, HIV infection, and particularly the
Acquired Immunodeﬁciency Syndrome (AIDS), has evolved
drastically from an acute lethal condition, with no therapeutic
options, to a chronic disease with multiple available therapeu-
tic regimens.2 Unfortunately, AIDS epidemic affects primarily
young adults, including a percentage of skilled educated per-
sons causing high economic impact. Furthermore, it is still
associated with stigma that could probably limit the response
to this epidemic.3 In Latin-America there are important dif-
ferences between countries. According to data from ONUSIDA
and CELADE, in 2010 there were 75,000 HIV-infected patients
in Peru with a prevalence of 2.5 per 1000 inhabitants, being
sexual intercourse the most important route of transmission
(97%).4
Highly active antiretroviral therapy (HAART) signiﬁcantly
reduced morbidity and mortality related to AIDS-deﬁning
opportunistic diseases (ODs).4 Since the introduction of
dideoxynucleoside reverse transcriptase inhibitors (NRTIs) in
1985 and after the approval of the ﬁrst protease inhibitor
in 1995, the availability of new ﬁxed-dose combinations
regimens of new antiretroviral drugs, evolved faster in the
developed world. Unfortunately, this is not the situation in
low-  and middle-income countries, especially in the rural
setting, where HIV now is common.5 The successful role of
HAART has extended life expectancy and enhanced the over-
all well-being of HIV-infected individuals. Moreover, recent
reports demonstrated that HAART could be useful strategy in
prevention, as well as in treatment, point out the importance
of drug adherence.4,5 In Peru, EsSalud, a major social security
health provider, incorporated HAART in 2001 with increas-
ing coverage, as the medical and patient communities readily
accepted it.4
However, there are increased concerns regarding HAART-
mediated metabolic derangements and its potential risk for
cardiovascular diseases (CVD) in the long term,1,3,5 espe-
cially when certain classes of antiretroviral drugs, such
as the protease inhibitors (PIs) are strongly implicated
in this process.6 CVD in HIV infection may result from
cardiac involvement upon presentation of ODs in the pres-
ence of advanced immunosuppression, be a consequence of
HIV-induced immune activation or derive from antiretrovi-
ral therapy-associated dyslipidemia and insulin resistance.7
Besides that, such consequences have not been particularly
addressed in Latin American countries, including Peru.1–7
CVD in patients with HIV infection, must be diagnosed
and treated, because there is growing incidence, due to fac-
tors associated with the infection or with the use of some
therapies.6 According to the Joint United Nations Program on
HIV and AIDS (UNAIDS) 2013 report, it has been estimated
that 35.3 million were infected all over the world in 2012
(32.2 million–38.8 million). However, the annual incidence of
new cases are decreasing as a consequence of HAART use.8
Nonetheless, if on one hand new complex therapeutic regi-
mens have favorably impacted life expectancy, on the other
hand some clinical situations like CVD or adverse events
have become very relevant.6,9 Investigations assessing these 1 5;1  9(4):431–435
negative consequences of HAART should be conducted in sett-
ings like Peru, where there have no previous studies.10–15
Therefore, the aim our study was to describe the CVD
complications as a cause of hospitalization in HIV-infected
patients, in every stage of disease, in a General Hospital of
Social Security in Lima, Peru.
We carried out a retrospective observational study (case
series) at the Edgardo Rebaglati Martins Hospital, a reference
hospital from Peruvian Social Security (EsSalud), with 1500
beds, at Lima, Peru. This report corresponds to the period
between January 1996 and December 2012.
Every hospitalization at the Infectious Diseases Unit dur-
ing the study period was reviewed, looking for the diagnosis
of HIV infection that ought to be described in the diagnosis
list ﬁlled in at hospital admission and discharge. At dis-
charge, diagnosis of “acute pericarditis”, “other diseases of
pericardium”, “unstable angina”, “acute myocardial infarc-
tion”, “myocarditis”, “acute and subacute endocarditis”, “heart
failure”, “cerebral infarction”, “intracerebral hemorrhage”,
“thrombophlebitis”, “pulmonary embolism”, and “primary
pulmonary hypertension”, according to ICD-10 classiﬁcation,
were reviewed.
Cardiovascular risk factors were deﬁned as follows: arterial
hypertension according to recommendations of the Sev-
enth Joint National Committee or if the patient reported to
be on hypertensive treatment; diabetes was deﬁned if the
patient had glucose level of 126 mg/dL or greater in two  sep-
arate occasions, or if the patient was on treatment for this
condition. Dyslipidemia was considered if the patient had
total cholesterol of 200 mg/dL or greater, or were receiving
hypocholesterolemic drugs. Obesity was considered when in
patients with a body mass index of 30 or greater. Finally,
a patient classiﬁed as smoker if he smoked any number of
cigarettes at the time of hospital admission or had quitted
smoking less than a year before.
Data of clinical records of the eligible patients were
abstracted using a form built for this study. Analysis was per-
formed using the Statistical Package for Social Science (SPSS)
version 21.0 (IBM Corporation 1994, 2014, USA). At descrip-
tive level numeric variables were presented as means and
standard deviations (SD) if they had normal distribution or
with medians and interquartile ranges (IQR) if they had not.
Categorical variables are showed as absolute frequencies and
percentages.
We included 26 hospitalized HIV-infected patients with
CVD in study period. No patient had more  than one hos-
pitalization for the same reason. Mean age was 46.3 years
(SD 12.5), and were predominantly male (57.7%). Ten patients
(38.4%) fulﬁlled the deﬁnition of AIDS. Out of the 17 (65.4%)
patients who had received HAART, eight had received pro-
tease inhibitors. The overall median time of HAART use was 48
months (IQR 72), and of HAART including protease inhibitors
was 72 months (IQR 90).
Prevalence of cardiovascular risk factors was low, with
15.4% with arterial hypertension and dyslipidemia, and type
2 diabetes or smoking in 7.7% (Table 1).
Eleven patients (42.3%) had some type of cardiac alteration
and 15 (57.7%) had some type of vascular non-cardiac prob-
lem. The most frequently cardiac alterations were pericardial
effusion (15.4%) and myocardial infarction (11.5%); among
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Table 1 – Demographic and clinical variables of
HIV-infected patients with cardiovascular diseases at
Edgardo Rebagliati Martins Hospital, Lima, Peru,
1996–2012.
Variable Mean (SD)/n (%)
Age (years) 46.3  (12.59)
30–75 (range)
Gender
Male 15 (57.7%)
Female 11 (42.3%)
Time of HIV diagnosis (months) 36  (12–72)
AIDS stage
Yes 10 (38.4%)
No 16 (61.6%)
CD4 count (cels/ul) 170  (20–323)
HAART
Yes 17 (65.4%)
Protease inhibitors 8 (30.7%)
No 9 (34.6%)
Cardiovascular risk factors
Arterial hypertension 4 (15.4%)
Dyslipidemia 4 (15.4%)
Type 2 diabetes 2 (7.7%)
Smoking 2 (7.7%)
Obesity 0 (0%)
Table 2 – Frequency of cardiovascular alterations of
HIV-infected patients with cardiovascular disease at
Edgardo Rebagliati Martins Hospital, Lima, Peru,
1996–2012.
Classiﬁcation n (%)
Cardiac alteration (n = 11)
Pericardial effusion 4 (15.4%)
Myocardial infarction 3 (11.5%)
Myocarditis 2 (7.7%)
Bacterial endocarditis 1 (3.85%)
Heart failure 1 (3.85%)
Vascular non-cardiac alteration (n = 15)
Deep vein thrombosis 6 (23.1%)
Cerebrovascular disease 5 (19.2%)
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pericardial effusion.Pulmonary hypertension 3 (11.5%)
Pulmonary embolism 1 (3.85%)
ascular non-cardiac alterations prevailed deep vein throm-
osis (23.1%) and cerebrovascular disease (19.2%) (Table 2).
Cardiac involvement in HIV-infected patients with AIDS
as ﬁrst described in 1983 by Autran who  reported myocar-
ial Kaposi sarcoma at autopsy. After that, there have been an
ncreased number of reports of cardiac involvement in AIDS
atients ranging between 28% and 73%. Moreover, in autopsy
eports of HIV-infected patients, the ﬁndings suggest that car-
iac involvement is rather common, possibly affecting more
han 73% of patients.16,17
However, with the increase of life expectancy of the HIV-
nfected population, the incidence of age-related diseases,
uch as CVD in older adults, have also increased. Such
ncrement in CVD has been related to aging, where some car-
iovascular risk factors like high blood pressure and diabetes,
s well as to the use of antiretroviral therapies, whose effect5;1 9(4):431–435 433
could be different depending on the therapeutic class and the
individual effects of every drug.17–20
Prevalence of these CVD in HIV-infected patients varies
from country of origin (developing or developed regions) and
according to the use of HAART and the type of therapy (includ-
ing protease inhibitors or not). On the other hand, vascular
involvement associated with HIV infection or its treatment
could be cardiac or non-cardiac.17–20
In Peru, there are some publications about the cardiac
involvement of HIV-infected patients. In a study of 164 ambu-
latory patients from Cayetano Heredia (Ministry of Health) and
Guillermo Almenara (Social Security, EsSalud), evaluated dur-
ing 2001 and 2002, using echocardiography, the prevalences of
CVD complications were: pericardial effusion 9.75%, systolic
dysfunction 1.82%, diastolic dysfunction 26.82%, restrictive
cardiomyopathy 0.60%, and pulmonary hypertension 2.43%.16
These results suggest that CVD could be present in patients
without cardiovascular symptoms, because none of them had
a previous positive cardiovascular evaluation.
In 2006, we  evaluated a group of ambulatory patients with
HIV infection who were on HAART. Arterial hypertension was
present in 3.26%, type 2 Diabetes in 1.81%, dyslipidemia in
34.05%, smoking in 3.96% and obesity in 4.71%.
Of this population, 4.16% who received protease inhibitors
had a high cardiovascular risk score according with Framing-
ham in comparison with patients who did not receive protease
inhibitors, which had a moderate cardiovascular risk score in
12.03% and a high cardiovascular risk score in 0.92%.21
In the present study, we described forms of cardiac and
non-cardiac vascular alterations, as causes for hospitaliza-
tion at Rebagliati hospital, a national reference hospital in the
country. Cardiac causes were pericardial effusion, myocardial
infarction, myocarditis, bacterial endocarditis and heart fail-
ure. None of these patients had cardiovascular risk factors
or were on antiretroviral therapy at the time of complica-
tion. Pericardial effusion was the most frequent cardiovascular
manifestation (4 cases). Study of the pericardial ﬂuid was not
performed according with the hospital protocols.
Pericardial effusion in patients with HIV infection could
be related with infections by opportunistic agents or malig-
nant neoplasms, but more  frequently the etiology is unknown.
Additionally, pericardial effusion could spontaneously resolve
in more  than 42%,7–9,16–18 considering that AIDS patients with
pericardial effusion have an annual incidence of cardiac tam-
ponade of 9%, and that 1% of patients with AIDS, annually
develop this medical condition.16
We  identiﬁed three cases of myocardial infarction, being
with ST elevation in two cases and with no ST elevation in one
case. ST elevation myocardial infarction had more  than two
cardiovascular risk factors (dyslipidemia and smoking; hyper-
tension, type 2 diabetes, dyslipidemia and smoking) and did
not receive ﬁbrinolytics or coronary angioplasty for the acute
phase, despite having formal indications to receive them. One
patient with ST elevation myocardial infarction died from sud-
den cardiac death three months after discharge. Moreover,
there was no case of myocardial infarction associated withThe relationship between viral infections and coronary
artery disease has not yet been fully established. Potential
mechanisms by which HIV virus could damage coronary
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arteries include the activation of cytokines and adhesion
molecules, and some alterations of class I tissue histocom-
patibility molecules in the surface of smooth muscle cells.11
However, in the last decades, there were reported cases
of acute coronary syndromes (unstable angina or myocar-
dial infarction) in patients with HIV infection who were
on antiretroviral therapy. Patients with additional risk fac-
tors, like arterial hypertension, type 2 diabetes, smoking,
or hyperhomocysteinemia could have an increased risk to
develop acute coronary syndromes or cerebrovascular disease,
because of accelerated atherosclerosis.16–19
We  found two cases of myocarditis, one case of heart fail-
ure, and another case of bacterial endocarditis. One case of
myocarditis was diagnosed in the debut of HIV infection and
the other case was a young woman with less than two years
of HIV diagnosis. The case of heart failure was diagnosed in a
patient with previous mitral valve involvement, and the case
of bacterial endocarditis was a patient without previous car-
diac disease, who  received empirical antibiotic therapy with
good response.
The rate of bacterial endocarditis in patients with HIV
infection is similar to other groups of risk, like IV drug users.
The prevalence varies from 6.3% to 34% in patients with
HIV infection, who are also IV drug users.7,8 It is possible to
ﬁnd cases of non-bacterial thrombotic endocarditis (maran-
tic endocarditis), and this is present in 3–5% of AIDS patients,
mainly in those with wasting syndrome.18,19
Cardiac involvement in HIV-infected patients was more
frequently present in AIDS patients. It has been published
that pericardial effusion and myocarditis could be present
in later stages of infection. On the other hand, myocardial
infarction, always severe, could be present in every stage of
disease.1,2,18–20
In our report, we described some cases of vascular non-
cardiac disease, like sic cases of deep vein thrombosis, ﬁve
cases of cerebrovascular disease, three cases of pulmonary
hypertension, and one case of pulmonary embolism. All of
the deep vein thrombosis cases received antiretroviral ther-
apy, and three of them received protease inhibitor agents. We
know that some antiretroviral agents, like protease inhibitors
induce insulin resistance, and then an increase of sympathet-
ical activity with sodium retention and subsequent arterial
hypertension. Other reports indicated that elevated blood
pressure could be related to lipodistrophy and other metabolic
disorders, especially in patients with hypertriglicerydemia.
Moreover, patients with HIV infection that develop fat distri-
bution, could have coagulation disorders like increased levels
of ﬁbrinogen, D-dimer, inhibitor of plasminogen activator, and
decreased levels of S protein. These abnormalities had been
associated with both arterial and venous thrombosis.10–15
All cases with cerebrovascular disease were ischemic and
affected individuals below 60 years of age (mean age 44.8
years). Four of them, were on antiretroviral therapy (two on
protease inhibitors). Only one of them had type 2 diabetes as
a cardiovascular risk factor.
Brain infarction or hemorrhage as manifestations of HIV
infection has been less studied. More  recent series of patients,
described a greater proportion of cases with brain infarction
(90–95% of cases) compared to hemorrhage (5–10% of cases).
In brain infarctions, the cause is found in most patients, and 1 5;1  9(4):431–435
disorders of coagulations are common. Deﬁciency in S pro-
tein, increased levels of IgG anti-phospholipid antibodies, and
anti-cardiolipin antibodies have been described. Most of the
patients in this series had lower than 500 CD4  cells/UL.10–15
Three cases had pulmonary hypertension not associ-
ated with cardiac or pulmonary disease. One case received
antiretroviral therapy without protease inhibitors. The inci-
dence of pulmonary hypertension associated with HIV
infection is approximately 1/200, a much greater incidence
than in the overall population, which is 1/200,000. This clin-
ical entity had been related with the presence of pulmonary
infections, IV drug abuse, factor VIII transfusion in hemophilic
patients, venous thromboembolism, heart failure, and the
presence of HLA-D26 and HLA-DR52.10–15
Vascular non-cardiac alterations in our case-series was
more  frequently observed than cardiac alterations, and were
associated with early stages of infection. In this report,
we evaluated vascular cardiac or non-cardiac atherosclerotic
complications, well deﬁned and presented in clinical studies
as cardiovascular endpoints. However, it is possible to detect
subclinical atherosclerosis measuring carotid intima-media
thickening (CIMT) or endothelial function using ﬂow mediated
brachial artery vasodilation.15
Compared to the pre-HAART era the number of deaths
has declined all over the world after HAART use. This had
been conﬁrmed by some epidemiological studies, like the
analysis of some centers controlled by US Department of
Defense. Then, 987 deaths in the pre-HAART era were regis-
tered, compared to 159 deaths in early-HAART, and 78 deaths
in well-established HAART era (p < 0.01). On the other hand,
there has been an increase of deaths not related to HIV infec-
tion by itself, and an increase in mortality due to cardiac
involvement (22% vs. 8%). In this case registry in particular,
cases between 1990 and 2003 were included and HAART was
initiated in 1997.14
In our study, there were three cases (11.53%) of deaths for
CVD. One patient died due to a massive cerebrovascular dis-
ease in the territory of middle cerebral artery, another due to
a sudden cardiac as a complication of myocardial infarction,
and the third patient due to pericardial effusion in a severely
immunosuppressed case.
In the INSERM registry in France, the causes of death in
patients with HIV infection in 2005 were compared to a pre-
vious evaluation performed in 2000. The percentage of death
related to AIDS declined from 47% to 36%. However, there was
an increase of three causes of death: neoplastic diseases, liver
diseases, and CVD.13
The number of hospitalizations in persons living with HIV
in the HAART era is not well known. However, the hospi-
talizations between 2001 and 2008 were evaluated in 11,645
individuals who received attention in US clinics. In this study,
the hospitalizations for AIDS-related diseases declined from
6.7 to 2.7 per 100-persons/year, and the AIDS-deﬁning infec-
tious diseases, psychiatric, or hepatic/CVD were stable or
diminished.11
Some demographic factors had been studied in 91,343
admissions in US between 2000 and 2004. In this report, the
mean age was between 41 and 44 years and the number of
diagnosis increased from 6 (2000) to 7.4 (2004), and the total
number of hospitalizations reduced by 39%.12
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In Latin America, after a careful review in bibliographic
atabases (Index Medicus/Medline, Scopus, Science Citation
ndex and SciELO), we did not ﬁnd studies related to cardio-
ascular causes of hospitalization in HIV patients. Therefore,
ur study, in spite of being descriptive and conducted in a sin-
le center, is relevant given the fact it describes for the ﬁrst
ime, cardiovascular events as hospitalization causes in HIV
atients.
It has been estimated that the number of cardiovascu-
ar or metabolic complications in patients infected with HIV
ill progressively increase, as result of the increase in life-
xpectancy. For 2015, it is estimated that more  than half of
he infected patients will be over 50 years of age in the US,
nd all over the world there will be increased number of cases
ith access to antiretroviral therapy.10–15
Finally, in our study, we found a group of patients hospital-
zed due to CVD, with an approximate frequency of one or two
ases per year. We  ﬁrstly described a group of vascular cardiac
nd non-cardiac diseases that prompted hospitalization HIV-
nfected patients in different stages of the disease. According
o our data, the presence of more  advanced immunosuppres-
ion could be associated with higher probability of cardiac
lterations. Further analytic studies in our country and at
egional settings are warranted.
unding
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